PE20000550A1 - Composicion de un derivado de bencimidazol util como anti-viral y anti-hiv - Google Patents
Composicion de un derivado de bencimidazol util como anti-viral y anti-hivInfo
- Publication number
- PE20000550A1 PE20000550A1 PE1999000422A PE00042299A PE20000550A1 PE 20000550 A1 PE20000550 A1 PE 20000550A1 PE 1999000422 A PE1999000422 A PE 1999000422A PE 00042299 A PE00042299 A PE 00042299A PE 20000550 A1 PE20000550 A1 PE 20000550A1
- Authority
- PE
- Peru
- Prior art keywords
- composition
- hiv
- benzimidazole derivative
- viral
- derivative useful
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 150000001556 benzimidazoles Chemical class 0.000 title abstract 2
- 230000036436 anti-hiv Effects 0.000 title 1
- 230000000840 anti-viral effect Effects 0.000 title 1
- 206010022000 influenza Diseases 0.000 abstract 2
- WJCNZQLZVWNLKY-UHFFFAOYSA-N thiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 abstract 2
- -1 4-THIAZOLYL Chemical group 0.000 abstract 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 abstract 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 abstract 1
- 241000702321 Microvirus Species 0.000 abstract 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- XYLGPCWDPLOBGP-UHFFFAOYSA-N chlorine nitrate Chemical compound ClON(=O)=O XYLGPCWDPLOBGP-UHFFFAOYSA-N 0.000 abstract 1
- 229940072253 epivir Drugs 0.000 abstract 1
- 125000001495 ethyl group Chemical class [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960004546 thiabendazole Drugs 0.000 abstract 1
- 235000010296 thiabendazole Nutrition 0.000 abstract 1
- 239000004308 thiabendazole Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE DE 250 mg A 6000 mg DE UN DERIVADO DE BENCIMIDAZOL DE FORMULA I, DONDE X ES H, HALOGENO, ALQUILO C1-C7, ALCOXI C1-C7; n ES 0-4; Y ES H, CLORO, NITRO, OXICLORO, METILO, ETILO; R ES H, ALQUILO C1-C8; R2 ES 4-TIAZOLILO, TAL COMO 2-(4-TIAZOLIL)BENCIMIDAZOL (TIABENDAZOL). TAMBIEN SE REFIERE A UNA COMPOSICION QUE COMPRENDE ADEMAS UN INHIBIDOR DE PROTEASA, AZIDOVUDINA (AZT), EPIVIR (3TC), DIDEOXICITOSINA (ddC), DIDEOXINOSINA (ddI). LA COMPOSICION PUEDE SER UTIL PARA PREVENIR EL DESARROLLO DE CEPAS DE VIRUS RESISTENTES AL VIH, SUPRIMIR EL VIH, INFLUENZA, RINOVIRUS, HEPATITIS, MICROVIRUS (HERPES O INFLUENZA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8138498A | 1998-05-19 | 1998-05-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20000550A1 true PE20000550A1 (es) | 2000-06-29 |
Family
ID=22163807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1999000422A PE20000550A1 (es) | 1998-05-19 | 1999-05-19 | Composicion de un derivado de bencimidazol util como anti-viral y anti-hiv |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6245789B1 (es) |
| EP (1) | EP1079831A1 (es) |
| JP (1) | JP2002515432A (es) |
| KR (1) | KR20010043709A (es) |
| CN (1) | CN1301158A (es) |
| AR (1) | AR019305A1 (es) |
| AU (1) | AU4004299A (es) |
| BR (1) | BR9911043A (es) |
| CA (1) | CA2329877A1 (es) |
| CO (1) | CO5050303A1 (es) |
| HU (1) | HUP0103319A2 (es) |
| ID (1) | ID27457A (es) |
| IL (1) | IL139002A0 (es) |
| NO (1) | NO20005839L (es) |
| PE (1) | PE20000550A1 (es) |
| PL (1) | PL344223A1 (es) |
| SK (1) | SK17442000A3 (es) |
| TR (1) | TR200003383T2 (es) |
| WO (1) | WO1999059585A1 (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6262093B1 (en) | 1995-04-12 | 2001-07-17 | The Proctor & Gamble Company | Methods of treating cancer with benzimidazoles |
| US6479526B1 (en) | 1995-04-12 | 2002-11-12 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of viruses and cancers |
| US6177460B1 (en) | 1995-04-12 | 2001-01-23 | The Procter & Gamble Company | Method of treatment for cancer or viral infections |
| US5770616A (en) | 1995-06-07 | 1998-06-23 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of cancers |
| US6265427B1 (en) | 1995-06-07 | 2001-07-24 | The Proctor & Gamble Company | Pharmaceutical composition for the method of treating leukemia |
| US6686391B2 (en) | 1995-08-04 | 2004-02-03 | University Of Arizona Foundation | N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions |
| US5900429A (en) | 1997-01-28 | 1999-05-04 | The Procter & Gamble Company | Method for inhibiting the growth of cancers |
| US6506783B1 (en) * | 1997-05-16 | 2003-01-14 | The Procter & Gamble Company | Cancer treatments and pharmaceutical compositions therefor |
| US6245789B1 (en) | 1998-05-19 | 2001-06-12 | The Procter & Gamble Company | HIV and viral treatment |
| US6423734B1 (en) * | 1999-08-13 | 2002-07-23 | The Procter & Gamble Company | Method of preventing cancer |
| US6242461B1 (en) * | 2000-01-25 | 2001-06-05 | Pfizer Inc. | Use of aryl substituted azabenzimidazoles in the treatment of HIV and AIDS related diseases |
| PE20020506A1 (es) | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
| US6380232B1 (en) | 2000-09-26 | 2002-04-30 | The Procter & Gamble Company | Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof |
| US6462062B1 (en) * | 2000-09-26 | 2002-10-08 | The Procter & Gamble Company | Compounds and methods for use thereof in the treatment of cancer or viral infections |
| US6407105B1 (en) * | 2000-09-26 | 2002-06-18 | The Procter & Gamble Company | Compounds and methods for use thereof in the treatment of cancer or viral infections |
| US6608096B1 (en) * | 2000-09-26 | 2003-08-19 | University Of Arizona Foundation | Compounds and methods for use thereof in the treatment of cancer or viral infections |
| WO2002041891A2 (en) * | 2000-11-01 | 2002-05-30 | The Procter & Gamble Company | Hiv treatment with benzimidazoles |
| JP2004515550A (ja) | 2000-12-15 | 2004-05-27 | グラクソ グループ リミテッド | 治療用化合物 |
| DE60112609T2 (de) | 2000-12-15 | 2006-01-19 | Glaxo Group Ltd., Greenford | Pyrazolopyridine |
| WO2002072581A2 (en) | 2001-03-08 | 2002-09-19 | Smithkline Beecham Corporation | Pyrazolopyriadine derivatives |
| EP1372643A1 (en) | 2001-03-30 | 2004-01-02 | Smithkline Beecham Corporation | Pyrazolopyridines, process for their preparation and use as therapeutic compounds |
| DE60212949T2 (de) | 2001-04-10 | 2007-01-04 | Smithkline Beecham Corp. | Antivirale pyrazolopyridin verbindungen |
| EP1385847B1 (en) | 2001-04-27 | 2005-06-01 | SmithKline Beecham Corporation | Pyrazolo[1,5-a]pyridine derivatives |
| PL366827A1 (en) | 2001-06-21 | 2005-02-07 | Smithkline Beecham Corporation | Imidazo[1,2-a]pyridine derivatives for the prophylaxis and treatment of herpes viral infections |
| ATE326466T1 (de) | 2001-10-05 | 2006-06-15 | Smithkline Beecham Corp | Imidazopyridinderivate zur verwendung bei der behandlung von herpes-vireninfektion |
| ES2292839T3 (es) | 2001-12-11 | 2008-03-16 | Smithkline Beecham Corporation | Derivados de pirazolo-piridina como agentes contra el herpes. |
| JP2005521712A (ja) * | 2002-03-26 | 2005-07-21 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ | 弱塩基の可溶化 |
| WO2004033454A1 (en) | 2002-10-03 | 2004-04-22 | Smithkline Beecham Corporation | Therapeutic compounds based on pyrazolopyridine derivatives |
| AU2003900064A0 (en) * | 2003-01-09 | 2003-01-23 | Penam Investments Pty. Ltd. | A method of treatment or prophylaxis of viral infection. |
| JP2005060362A (ja) * | 2003-07-28 | 2005-03-10 | Shionogi & Co Ltd | セスキテルペン誘導体を含有する抗ＨＩＶ剤、抗ＢＶＤＶ剤、抗ＨＣＶ剤又は抗ＣｏＶ剤 |
| EP2251010A1 (en) | 2009-05-08 | 2010-11-17 | Sygnis Bioscience GmbH & Co. KG | Use of thiabendazole and derivatives thereof for the therapy of neurological conditions |
| CA2905375A1 (en) * | 2013-03-15 | 2014-09-18 | Camas Incorporated | Methods and compositions for reducing microorganisms in the oropharynx, nasopharynx and oral cavities |
| FR3057865A1 (fr) * | 2016-10-21 | 2018-04-27 | Laboratoire Michel Iderne | Composition chimique |
| TW201936193A (zh) * | 2017-12-05 | 2019-09-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 使用組合產品治療ｒｓｖ |
| KR102342313B1 (ko) | 2021-08-27 | 2021-12-24 | (주)바이오메트릭스 테크놀로지 | 벤지미다졸-탄수화물 결합체 화합물을 포함하는 미셀, 이의 제조방법, 이의 항암제 또는 항바이러스제로서의 용도 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3010968A (en) | 1959-11-25 | 1961-11-28 | Du Pont | Process for manufacture of certain alkyl esters of benzimidazole carbamic acids |
| NL134354C (es) | 1963-05-23 | |||
| US3499761A (en) | 1964-07-20 | 1970-03-10 | Gaf Corp | Silver halide emulsions containing alkyl esters of benzimidazole carbamic acid antifogging agents |
| US3541213A (en) | 1966-05-06 | 1970-11-17 | Du Pont | Fungicidal and mite ovicidal substituted 2-aminobenzimidazoles |
| US3881014A (en) | 1968-11-05 | 1975-04-29 | Bayer Ag | N-tritylimidazoles for treating fungal infections |
| BE759337A (fr) | 1969-11-24 | 1971-05-24 | Lilly Co Eli | Benzimidazol (2,1-b)-quinazolin (6h) ones qui sont des immuno-depresseurs, et nouvelles benzimidazo (2,1-b) quinazolin-12-(6h) ones |
| US3956262A (en) | 1970-12-09 | 1976-05-11 | Beecham Group Limited | Triazenoimidazoles |
| US3738995A (en) | 1971-05-14 | 1973-06-12 | Du Pont | Solvent process for the preparation of 1 - carbamoyl-substituted 2 - benzimidazolecarbamates |
| FR2155888A1 (en) | 1971-10-13 | 1973-05-25 | Agot Aime | Solid anthelmintic composn - for more economical treatment of ruminants |
| US4046906A (en) | 1973-04-21 | 1977-09-06 | Hoechst Aktiengesellschaft | Salts of alkyl 2-benzimidazole-carbamate |
| HU193951B (en) | 1985-03-11 | 1987-12-28 | Richter Gedeon Vegyeszet | Process for producing new sulfur-containing 5-substituted benzimidazol derivatives and pharmaceutical compositions containing them |
| US4731366A (en) | 1986-08-05 | 1988-03-15 | Harbor Branch Oceanographic Institution, Inc. | Discorhabdin compositions and their methods of use |
| GB2210875B (en) | 1987-10-09 | 1991-05-29 | Farmos Oy | Aromatase inhibiting 4(5)-imidazoles |
| US5329012A (en) | 1987-10-29 | 1994-07-12 | The Research Foundation Of State University Of New York | Bis(acyloxmethyl)imidazole compounds |
| US5114951A (en) | 1989-04-11 | 1992-05-19 | Burroughs Wellcome Company | Agents for combating multiple drug resistance |
| US5149527A (en) | 1990-09-18 | 1992-09-22 | Oncotech, Inc. | Immunopotentiating protocol for chemotherapy-responsive tumors |
| US5310748A (en) | 1992-05-11 | 1994-05-10 | The Du Pont Merck Pharmaceutical Company | Imidazoles for the treatment of atherosclerosis |
| US5364875A (en) | 1992-05-11 | 1994-11-15 | The Du Pont Merck Pharmaceutical Company | Imidazoles linked to bicyclic heterocyclic groups for the treatment of atherosclerosis |
| US5290801A (en) | 1992-05-29 | 1994-03-01 | The Du Pont Merck Pharmaceutical Company | Benzimidazoles for the treatment of atherosclerosis |
| JPH08500112A (ja) | 1992-08-12 | 1996-01-09 | ジ・アップジョン・カンパニー | タキソールと組み合わせるプロテインキナーゼ阻害剤および関連化合物 |
| KR100311551B1 (ko) | 1993-03-31 | 2001-12-28 | 폴락 돈나 엘. | Aids 치료용 약제학적 배합물 중의 hiv 프로테아제 억제제 |
| US5434163A (en) | 1993-05-14 | 1995-07-18 | The Medical College Of Pennsylvania | Treatment of Cryptococcus neoformans infection |
| JP3213471B2 (ja) | 1994-04-13 | 2001-10-02 | ポーラ化成工業株式会社 | 薬効成分含有リポソーム製剤の製造方法 |
| ZA962880B (en) | 1995-04-12 | 1997-03-17 | Procter & Gamble | A pharmaceutical composition for inhibiting the growth of viruses and cancers |
| ZA962879B (en) * | 1995-04-12 | 1997-03-17 | Procter & Gamble | A pharmaceutical composition for inhibiting the growth of viruses and cancers |
| US5656615A (en) | 1995-04-12 | 1997-08-12 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of cancers and viruses in mammals |
| JPH11503460A (ja) | 1995-04-12 | 1999-03-26 | ザ プロクター アンド ギャンブル カンパニー | ウィルスおよび癌の増殖を阻止するｎ−クロロフェニルカルバメートおよびｎ−クロロフェニルチオカルバメート含有医薬組成物 |
| NZ305784A (en) | 1995-04-12 | 2001-03-30 | Procter & Gamble | Benzimidazole containing medicaments for treating cancers, tumors and viral infections |
| US5629341A (en) | 1995-04-12 | 1997-05-13 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of viruses and cancers |
| US5665713A (en) | 1995-04-12 | 1997-09-09 | Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of viruses and cancers |
| US6200992B1 (en) | 1995-06-07 | 2001-03-13 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of cancers |
| US5665751A (en) | 1995-06-07 | 1997-09-09 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of cancers |
| MX9707809A (es) | 1995-06-07 | 1998-01-31 | Procter & Gamble | Una composicion farmaceutica que contiene bencimidazol para inhibir el crecimiento de canceres. |
| CZ391197A3 (cs) | 1995-06-07 | 1998-05-13 | The Procter & Gamble Company | Použití benzimidazolů pro přípravu léčiva pro léčení leukémie |
| US5770616A (en) | 1995-06-07 | 1998-06-23 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of cancers |
| MX9800945A (es) | 1995-08-03 | 1998-04-30 | Procter & Gamble | Uso de griseofulvina para inhibir el crecimiento de canceres. |
| US5908855A (en) | 1996-07-16 | 1999-06-01 | The Procter & Gamble Company | Compositions for treating viral infections |
| JPH11510187A (ja) | 1995-08-04 | 1999-09-07 | ザ プロクター アンド ギャンブル カンパニー | 癌の成長を阻害するためのフルコナゾールの使用 |
| US5900429A (en) | 1997-01-28 | 1999-05-04 | The Procter & Gamble Company | Method for inhibiting the growth of cancers |
| PE11499A1 (es) | 1997-05-16 | 1999-03-01 | Procter & Gamble | Tratamiento del hiv y cancer |
| US6506783B1 (en) | 1997-05-16 | 2003-01-14 | The Procter & Gamble Company | Cancer treatments and pharmaceutical compositions therefor |
| US6245789B1 (en) | 1998-05-19 | 2001-06-12 | The Procter & Gamble Company | HIV and viral treatment |
-
1999
- 1999-05-17 US US09/312,949 patent/US6245789B1/en not_active Expired - Fee Related
- 1999-05-19 CN CN99806363A patent/CN1301158A/zh active Pending
- 1999-05-19 SK SK1744-2000A patent/SK17442000A3/sk unknown
- 1999-05-19 EP EP99923219A patent/EP1079831A1/en not_active Withdrawn
- 1999-05-19 PL PL99344223A patent/PL344223A1/xx unknown
- 1999-05-19 WO PCT/US1999/011059 patent/WO1999059585A1/en not_active Ceased
- 1999-05-19 CO CO99030834A patent/CO5050303A1/es unknown
- 1999-05-19 ID IDW20002656A patent/ID27457A/id unknown
- 1999-05-19 AR ARP990102384A patent/AR019305A1/es unknown
- 1999-05-19 IL IL13900299A patent/IL139002A0/xx unknown
- 1999-05-19 HU HU0103319A patent/HUP0103319A2/hu unknown
- 1999-05-19 AU AU40042/99A patent/AU4004299A/en not_active Abandoned
- 1999-05-19 JP JP2000549250A patent/JP2002515432A/ja not_active Withdrawn
- 1999-05-19 CA CA002329877A patent/CA2329877A1/en not_active Abandoned
- 1999-05-19 BR BR9911043-1A patent/BR9911043A/pt not_active IP Right Cessation
- 1999-05-19 PE PE1999000422A patent/PE20000550A1/es not_active Application Discontinuation
- 1999-05-19 KR KR1020007012938A patent/KR20010043709A/ko not_active Ceased
- 1999-05-19 TR TR2000/03383T patent/TR200003383T2/xx unknown
-
2000
- 2000-11-17 NO NO20005839A patent/NO20005839L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CO5050303A1 (es) | 2001-06-27 |
| WO1999059585A1 (en) | 1999-11-25 |
| AR019305A1 (es) | 2002-02-13 |
| US6245789B1 (en) | 2001-06-12 |
| CN1301158A (zh) | 2001-06-27 |
| KR20010043709A (ko) | 2001-05-25 |
| NO20005839D0 (no) | 2000-11-17 |
| JP2002515432A (ja) | 2002-05-28 |
| CA2329877A1 (en) | 1999-11-25 |
| NO20005839L (no) | 2001-01-16 |
| EP1079831A1 (en) | 2001-03-07 |
| SK17442000A3 (sk) | 2001-08-06 |
| TR200003383T2 (tr) | 2001-03-21 |
| IL139002A0 (en) | 2001-11-25 |
| BR9911043A (pt) | 2001-02-13 |
| ID27457A (id) | 2001-04-12 |
| AU4004299A (en) | 1999-12-06 |
| HUP0103319A2 (hu) | 2002-05-29 |
| PL344223A1 (en) | 2001-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20000550A1 (es) | Composicion de un derivado de bencimidazol util como anti-viral y anti-hiv | |
| PE20100363A1 (es) | Composiciones que comprenden nucleosidos | |
| ATE306261T1 (de) | Antithrombosemittel | |
| EA200100541A1 (ru) | Фармацевтическая композиция с модифицированным высвобождением сенсибилизатора к инсулину и других антидиабетических агентов | |
| AR067030A2 (es) | Composiciones farmaceuticas | |
| AR041089A1 (es) | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas | |
| PE20001036A1 (es) | Tabletas bioadhesivas para hidratacion progresiva y metodos para su elaboracion y uso | |
| BR9916772A (pt) | Quinolinacarboxamidas como agentes antivirais | |
| NO20052010L (no) | Immunogen sammensetning | |
| AR029825A1 (es) | Una composicion farmaceuticamente aceptable que comprende carvedilol o una sal del mismo farmaceuticamente aceptable, un procedimiento para la produccion de dicha composicion y utilizacion de la misma | |
| CL2004002061A1 (es) | Compuestos derivados de heterociclos condensados que contienen nitrogeno; composicion farmaceutica; y su uso como agente antiviral, inhubidor de integrasa y como agente anti-vih. | |
| AR098808A2 (es) | Una forma de dosificación farmacéutica de fusión instantánea que se desintegrará en la boca en un tiempo de 25 segundos | |
| ES2165833T1 (es) | Composicion farmaceutica revestida enterica y procedimiento de fabricacion. | |
| BR0108816A (pt) | Derivados de quinolina como antagonistas alfa-2 | |
| MX2022002072A (es) | Metodo para incorporar acido oleanolico en composiciones para el cuidado oral y composiciones para el cuidado oral a base de estas. | |
| AR012621A1 (es) | Composiciones organicas | |
| PE20010071A1 (es) | Composicion de un inhibidor de pde5 | |
| ECSP055869A (es) | Vacuna hpv-16 y -18 l1 vlp | |
| PE61699A1 (es) | Composicion farmaceutica de lamivudina | |
| PT833640E (pt) | Composicao farmaceutica contendo lamotrigina | |
| TR200000153T2 (tr) | İl-5 inhibite eden 6-azaurasil türevleri. | |
| CO5170467A1 (es) | Capsulas de eter de celulosa libres de turbiedad y proceso para hacer las mismas | |
| ES2061498T3 (es) | Composiciones espesadas para moldeo. | |
| ES2093682T3 (es) | Composiciones de isotiazolona diluibles en agua. | |
| BRPI0607214B8 (pt) | derivados de 2-(4-cianofenilamino)pirimidina inibidores de hiv, composição farmacêutica que os compreende e seus processos de preparação |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |